A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

BACKGROUND: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnitzbauer, Andreas A, Zuelke, Carl, Graeb, Christian, Rochon, Justine, Bilbao, Itxarone, Burra, Patrizia, de Jong, Koert P, Duvoux, Christophe, Kneteman, Norman M, Adam, Rene, Bechstein, Wolf O, Becker, Thomas, Beckebaum, Susanne, Chazouillères, Olivier, Cillo, Umberto, Colledan, Michele, Fändrich, Fred, Gugenheim, Jean, Hauss, Johann P, Heise, Michael, Hidalgo, Ernest, Jamieson, Neville, Königsrainer, Alfred, Lamby, Philipp E, Lerut, Jan P, Mäkisalo, Heikki, Margreiter, Raimund, Mazzaferro, Vincenzo, Mutzbauer, Ingrid, Otto, Gerd, Pageaux, Georges-Philippe, Pinna, Antonio D, Pirenne, Jacques, Rizell, Magnus, Rossi, Giorgio, Rostaing, Lionel, Roy, Andre, Turrion, Victor Sanchez, Schmidt, Jan, Troisi, Roberto I, van Hoek, Bart, Valente, Umberto, Wolf, Philippe, Wolters, Heiner, Mirza, Darius F, Scholz, Tim, Steininger, Rudolf, Soderdahl , Gunnar, Strasser, Simone I, Jauch, Karl-Walter, Neuhaus, Peter, Schlitt, Hans J, Geissler, Edward K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889889/
https://www.ncbi.nlm.nih.gov/pubmed/20459775
http://dx.doi.org/10.1186/1471-2407-10-190

Ejemplares similares

Ejemplares similares